Scholar Rock Holding (SRRK) Research & Development (2017 - 2026)
Scholar Rock Holding's quarterly Research & Development came in at $51.8 million in Q1 2026, up 6.44% year-on-year from $48.7 million in Q1 2025, and up 10.54% quarter-over-quarter from $46.9 million in Q4 2025.
Scholar Rock Holding has reported Research & Development for 10 years, with the latest figure at $51.8 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 6.44% year-over-year to $51.8 million; the trailing twelve-month figure through Mar 2026 stood at $211.6 million (up 11.28% YoY), and the FY2025 full-year result was $208.4 million, up 12.95% from the prior year.
- Research & Development for Q1 2026 stood at $51.8 million, up from $46.9 million in the prior quarter.
- The five-year high for Research & Development was $62.4 million in Q2 2025, with the low at $26.9 million in Q2 2023.
- Average Research & Development over 5 years is $40.7 million, with a median of $42.4 million recorded in 2024.
- Year-over-year, Research & Development slipped 16.23% in 2023 and soared 60.59% in 2024.
- Tracing SRRK's Research & Development over 5 years: stood at $29.6 million in 2022, then advanced by 18.06% to $35.0 million in 2023, then jumped by 44.06% to $50.4 million in 2024, then retreated by 6.93% to $46.9 million in 2025, then grew by 10.54% to $51.8 million in 2026.
- The last three Research & Development figures came in at $51.8 million (Q1 2026), $46.9 million (Q4 2025), and $50.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 51.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.81 Mn |
| Dec 31, 2025 | 46.88 Mn |
| Sep 30, 2025 | 50.49 Mn |
| Jun 30, 2025 | 62.40 Mn |
| Mar 31, 2025 | 48.68 Mn |
| Dec 31, 2024 | 50.37 Mn |
| Sep 30, 2024 | 48.72 Mn |
| Jun 30, 2024 | 42.37 Mn |
| Mar 31, 2024 | 43.09 Mn |
| Dec 31, 2023 | 34.96 Mn |
| Sep 30, 2023 | 30.34 Mn |
| Jun 30, 2023 | 26.87 Mn |
| Mar 31, 2023 | 29.74 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 33.39 Mn |
| Jun 30, 2022 | 32.07 Mn |
| Mar 31, 2022 | 29.37 Mn |
| Dec 31, 2021 | 29.05 Mn |
| Sep 30, 2021 | 31.27 Mn |
| Jun 30, 2021 | 25.60 Mn |
| Mar 31, 2021 | 22.55 Mn |
| Dec 31, 2020 | 21.78 Mn |
| Sep 30, 2020 | 18.38 Mn |
| Jun 30, 2020 | 17.00 Mn |
| Mar 31, 2020 | 16.90 Mn |
| Dec 31, 2019 | 14.06 Mn |
| Sep 30, 2019 | 15.70 Mn |
| Jun 30, 2019 | 13.72 Mn |
| Mar 31, 2019 | 10.74 Mn |
| Dec 31, 2018 | 10.13 Mn |
| Sep 30, 2018 | 8.06 Mn |
| Jun 30, 2018 | 11.42 Mn |
| Mar 31, 2018 | 6.70 Mn |
| Dec 31, 2017 | 6.89 Mn |
| Sep 30, 2017 | 4.78 Mn |
| Jun 30, 2017 | 4.71 Mn |